The current financial score of Inhibrx Biosciences Inc is 7.34. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 0.00, representing a year-over-year decrease of 100.00%, while its net profit experienced a year-over-year decrease of 27.91%.
The current valuation score of Inhibrx Biosciences Inc is 9.80. Its current P/E ratio is -11.96, which is -101.21% below the recent high of 0.14 and -31.14% above the recent low of -15.68.
The current earnings forecast score of Inhibrx Biosciences Inc is 8.00. The average price target is 266.67, with a high of 325.00 and a low of 230.00.
The current price momentum score of Inhibrx Biosciences Inc is 4.73. Currently, the stock price is trading between the resistance level at 122.89 and the support level at 85.88, making it suitable for range-bound swing trading.
The current institutional shareholding score of Inhibrx Biosciences Inc is 7.00. The latest institutional shareholding proportion is 84.51%, representing a quarter-over-quarter increase of 25.28%.
The current risk assessment score of Inhibrx Biosciences Inc is 4.66. The company's beta value is 0.00. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.